Search results
Showing 801 to 850 of 1834 results for carers
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Awaiting development Reference number: GID-TA10961 Expected publication date: TBC
In development Reference number: GID-TA11130 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.
In development Reference number: GID-TA11694 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 20 February 2026.
Evidence-based recommendations on tenecteplase (Metalyse) for treating acute ischaemic stroke in adults.
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]
In development Reference number: GID-TA11071 Expected publication date: TBC
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
PillCam COLON 2 for investigation of the colon through direct visualisation
In development Reference number: GID-DG10083 Expected publication date: TBC
In development Reference number: GID-TA11162 Expected publication date: 28 July 2027
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia
Awaiting development Reference number: GID-MT599 Expected publication date: TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
Monofocal intraocular lenses for cataract surgery (provisional title)
In development Reference number: GID-HTE10090 Expected publication date: TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor
In development Reference number: GID-IPG10441 Expected publication date: TBC
We are listening to your views on this Interventional procedures guidance. Comments close 11 February 2026.
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]
Awaiting development Reference number: GID-TA11509 Expected publication date: TBC
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
In development Reference number: GID-TA11410 Expected publication date: TBC
In development Reference number: GID-TA11497 Expected publication date: TBC
Awaiting development Reference number: GID-TA11343 Expected publication date: TBC
In development Reference number: GID-TA11336 Expected publication date: TBC
Artificial intelligence software to help detect and characterise colorectal polyps
In development Reference number: GID-DG10118 Expected publication date: TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
In development Reference number: GID-TA11501 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.
Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRI
In development Reference number: GID-HTE10089 Expected publication date: TBC
This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.
View quality statements for QS121Show all sections
Sections for QS121
- Quality statements
- Quality statement 1: Advice on self-limiting conditions
- Quality statement 2: Back-up (delayed) prescribing
- Quality statement 3: Recording information
- Quality statement 4: Microbiological samples
- Quality statement 5: Data collection and feedback
- Quality statement 6 (developmental statement): electronic prescribing systems
- Update information
whose care is covered by the quality standard (for example user, patient, carer, charity and other non-governmental organisations). Take...
whose care is covered by the quality standard (for example user, patient, carer, charity and other non-governmental organisations). Take...
People can comment on our guidance at specific stages in its development.
People can comment on our guidance at specific stages in its development.
This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS97Show all sections
Sections for QS97
- Quality statements
- Quality statement 1: Documentation using the structured assessment guide
- Quality statement 2: Advice about carrying personal structured drug information
- Quality statement 3: Referral to specialist drug allergy services
- Quality statement 4: Recording drug allergy status in electronic medical records
- Quality statement 5: Updating information on drug allergy status
- Quality statement 6 (developmental): Prescription information on drug avoidance
- About this quality standard
In development Reference number: GID-TA11544 Expected publication date: 14 May 2026
Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant
In development Reference number: GID-HTE10084 Expected publication date: TBC
In development Reference number: GID-HTE10080 Expected publication date: TBC
In development Reference number: GID-IPG10405 Expected publication date: 19 November 2026
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Technology appraisal submission templates and supporting documents
All the templates and supporting documents you need to make a technology appraisals submission with NICE.
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.
In development Reference number: GID-TA11402 Expected publication date: TBC
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
Vagus nerve stimulation for refractory epilepsy in children (HTG25)
Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.
View recommendations for HTG25Show all sections
Sections for HTG25
Pancreatic cancer in adults: diagnosis and management (NG85)
This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Awaiting development Reference number: GID-TA11018 Expected publication date: TBC